Abstract
In two consecutive randomized placebo-control trials, DHA has been used in combination with other micronutrient vitamins (choline (CHO), vitamin E as alpha-tocopherol and vitamin D) to treat obese nonalcoholic steatohepatitis (NASH) patients along with dietary restriction and physical activity. Regardless of micronutrient vitamins combination, the two DHA-based trials resulted in an improved liver echogenicity (primary end-point), NAFLD Activity Score (NAS) that included biopsy-derived fibrosis and steatosis indices, and metabolic parameters such as fasting blood glucose, LDL, triglycerides and AST. In these trials increased concentrations of plasma free DHA and, even more, a decreased AA/DHA ratio were the strongest predictors of the clinical outcome. A stable correction of DHA concentrations and metabolism may thus represent a major nutritional end-point and precious indicator in the clinical management of pediatric NASH. DHA therapy deserves further investigation as a first-lane intervention in these patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
